stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.06
0.70
+4.03%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Net income
Dyne Therapeutics, Inc.'s net income for fiscal 2025 was −$446.2M, compared with −$317.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$519.4M. Over the past ten years it has ranged from −$446.2M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 8 consecutive fiscal years. Dyne Therapeutics, Inc. ranks 586th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$446.2M | — |
| FY2024 | −$317.4M | — |
| FY2023 | −$235.9M | — |
| FY2022 | −$168.1M | — |
| FY2021 | −$149.3M | — |
| FY2020 | −$59.4M | — |
| FY2019 | −$14.9M | — |
| FY2018 | −$4.8M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$178.6M | — |
| Mar 2026 | −$120.9M | — |
| Dec 2025 | −$112.0M | — |
| Sep 2025 | −$108.0M | — |
| 24 more quarters | Free account |
Against its own ten years
Low −$446.2M
High $0.00
Ten-year median
−$149.3M
Current reading's percentile
11
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item